Amgen’s mysterious obesity asset will remain a mystery for a bit longer—the FDA has put the candidate’s phase 1 trial ...

Q32 Bio has stopped a Phase II trial of its former lead renal disease candidate as it focuses on its alopecia areata ...

Amgen posted a higher quarterly profit on Tuesday as product sales rose 11% and said late-stage studies of key obesity drug ...

Shares of the company began plunging in November, but its overall strength should set the stock up for some serious potential ...

Amgen Inc. sees the potential for 2025 revenues to top Wall Street estimates thanks to growth in cholesterol and cancer drugs ...

The company said the agency's hold was "not related to the drug,” dubbed AMG 513, and that discussions were underway to ...

Shares of Amgen (Nasdaq: AMGN) started crashing in early November and didn’t improve when the company released data from a ...

Amgen outperformed expectations in the fourth quarter of 2024, but revealed an FDA hold on early-stage obesity asset AMG 513 ...

Amgen's Q4 earnings beat expectations, showcasing robust performance for the company's growth strategy. Click here to read ...

Individual patient data from neoadjuvant randomized breast cancer clinical trials with available data on pathologic complete ...

All lines have been placed on mute to prevent any background noise. There will be a question-and-answer session at the ...

Research from the Tufts Center for the Study of Drug Development’s PACT Consortium shows DCTs encourage higher participation ...